These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 21505104)
1. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Zhang H; Pan Y; Zheng L; Choe C; Lindgren B; Jensen ED; Westendorf JJ; Cheng L; Huang H Cancer Res; 2011 May; 71(9):3257-67. PubMed ID: 21505104 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of FOXO1/3 promotes vascular calcification. Deng L; Huang L; Sun Y; Heath JM; Wu H; Chen Y Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):175-83. PubMed ID: 25378413 [TBL] [Abstract][Full Text] [Related]
3. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. Liu P; Li S; Gan L; Kao TP; Huang H Cancer Res; 2008 Dec; 68(24):10290-9. PubMed ID: 19074897 [TBL] [Abstract][Full Text] [Related]
4. Foxo1 mediates insulin-like growth factor 1 (IGF1)/insulin regulation of osteocalcin expression by antagonizing Runx2 in osteoblasts. Yang S; Xu H; Yu S; Cao H; Fan J; Ge C; Fransceschi RT; Dong HH; Xiao G J Biol Chem; 2011 May; 286(21):19149-58. PubMed ID: 21471200 [TBL] [Abstract][Full Text] [Related]
5. FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants. Bohrer LR; Liu P; Zhong J; Pan Y; Angstman J; Brand LJ; Dehm SM; Huang H Prostate; 2013 Jul; 73(10):1017-27. PubMed ID: 23389878 [TBL] [Abstract][Full Text] [Related]
6. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis. Bai Y; Yang Y; Yan Y; Zhong J; Blee AM; Pan Y; Ma T; Karnes RJ; Jimenez R; Xu W; Huang H Theranostics; 2019; 9(12):3459-3475. PubMed ID: 31281490 [No Abstract] [Full Text] [Related]
7. Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer. Wu Z; He B; He J; Mao X Prostate; 2013 May; 73(6):596-604. PubMed ID: 23060044 [TBL] [Abstract][Full Text] [Related]
8. Decreased expression of ARHGAP15 promotes the development of colorectal cancer through PTEN/AKT/FOXO1 axis. Pan S; Deng Y; Fu J; Zhang Y; Zhang Z; Ru X; Qin X Cell Death Dis; 2018 Jun; 9(6):673. PubMed ID: 29867200 [TBL] [Abstract][Full Text] [Related]
9. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Akech J; Wixted JJ; Bedard K; van der Deen M; Hussain S; Guise TA; van Wijnen AJ; Stein JL; Languino LR; Altieri DC; Pratap J; Keller E; Stein GS; Lian JB Oncogene; 2010 Feb; 29(6):811-21. PubMed ID: 19915614 [TBL] [Abstract][Full Text] [Related]
10. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer. Yan Y; Huang H Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915 [TBL] [Abstract][Full Text] [Related]
11. MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2. Colden M; Dar AA; Saini S; Dahiya PV; Shahryari V; Yamamura S; Tanaka Y; Stein G; Dahiya R; Majid S Cell Death Dis; 2017 Jan; 8(1):e2572. PubMed ID: 28125091 [TBL] [Abstract][Full Text] [Related]
12. Long‑term exposure to leptin enhances the growth of prostate cancer cells. Noda T; Kikugawa T; Tanji N; Miura N; Asai S; Higashiyama S; Yokoyama M Int J Oncol; 2015 Apr; 46(4):1535-42. PubMed ID: 25625287 [TBL] [Abstract][Full Text] [Related]
13. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer. Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199 [No Abstract] [Full Text] [Related]
14. Stimulation of the Runx2 P1 promoter by collagen-derived dipeptide prolyl-hydroxyproline bound to Foxg1 and Foxo1 in osteoblasts. Nomura K; Kimira Y; Osawa Y; Kataoka-Matsushita A; Takao K; Sugita Y; Shimizu J; Wada M; Mano H Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34779485 [TBL] [Abstract][Full Text] [Related]
15. A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT signal pathway in prostate cancer. Su B; Gao L; Baranowski C; Gillard B; Wang J; Ransom R; Ko HK; Gelman IH PLoS One; 2014; 9(7):e101411. PubMed ID: 24983969 [TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. Fan W; Yanase T; Morinaga H; Okabe T; Nomura M; Daitoku H; Fukamizu A; Kato S; Takayanagi R; Nawata H J Biol Chem; 2007 Mar; 282(10):7329-38. PubMed ID: 17202144 [TBL] [Abstract][Full Text] [Related]
17. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Chua CW; Chiu YT; Yuen HF; Chan KW; Man K; Wang X; Ling MT; Wong YC Clin Cancer Res; 2009 Jul; 15(13):4322-35. PubMed ID: 19509141 [TBL] [Abstract][Full Text] [Related]
18. Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Baniwal SK; Khalid O; Gabet Y; Shah RR; Purcell DJ; Mav D; Kohn-Gabet AE; Shi Y; Coetzee GA; Frenkel B Mol Cancer; 2010 Sep; 9():258. PubMed ID: 20863401 [TBL] [Abstract][Full Text] [Related]
19. Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion. Yang Y; Blee AM; Wang D; An J; Pan Y; Yan Y; Ma T; He Y; Dugdale J; Hou X; Zhang J; Weroha SJ; Zhu WG; Wang YA; DePinho RA; Xu W; Huang H Cancer Res; 2017 Dec; 77(23):6524-6537. PubMed ID: 28986382 [TBL] [Abstract][Full Text] [Related]
20. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]